Table I.
Anti-phospholipid monoclonal antibodies in this study
| mAb | Heavy chain | Light chain | Binds cardiolipin/PS | Binds HIV-1 Env | Binds directly to β2GP1 | Binding to CL/PS dependent on β2GP1 | mAb origin |
| IS4 | γ3 VH1 | λ Vλ2 | ++ | − | + | Yes | APS subject |
| CL1 | γ3 VH1 | λ Vλ3 | ++ | − | ++ | No | SLE subject with APS |
| P1 | γ1 | λ | ++ | − | +++ | No | SLE subject with APS |
| PGN632 | γ1 | λ | ++ | − | + | No | uninfected and healthy subjecta |
| PGN401 | γ1 | κ | + | − | + | Yes | humanized mouse mAb |
| B1 | γ1 | κ | + | − | +++ | Yes | APS subject |
| B2 | γ3 | κ | ++ | − | + | Yes | APS subject |
| PGN635 | γ1 | λ | + | − | + | Yes | uninfected and healthy subjecta |
| PGN634 | γ1 | λ | + | − | + | Yes | uninfected and healthy subjecta |
| 2F5 | γ3 | κ | + | + | + | No | HIV-1 + subject |
| 4E10 | γ3 | κ | + | + | + | No | HIV-1 + subject |
a
Derived from an antibody library from normal subjects. PGN632 was further engineered to optimize binding to PS.